Hematologic Malignancies
ASCO & ASH: Translating Data Into Decisions
The Latest: CLL
Insights & Perspectives
Latest Therapies For Managing Patients With Treatment-Naive CLL: Comparing Calquence, Imbruvica, and Brukinsa
Staying Connected & Sharing Knowledge: How Community Doctors Can Stay on Top of the Latest in CLL Research
For Treatment-Naïve CLL: The Risks & Benefits of Time-Limited Therapy vs. Continuous Therapy
When To Treat Chronic Lymphocytic Leukemia (CLL)?
Improving Quality of Life for Immunocompromised CLL Patients
Continuous Therapy Options For CLL: Acalabrutinib vs. Zanubrutinib
The Latest: Multiple Myeloma
Monitoring For Differentiation Syndrome
multiple myeloma
Differentiation Syndrome in the Era of Targeted Therapies for Acute Myeloid Leukemia
Differentiation syndrome (DS) has re-emerged as a clinically significant toxicity with the advent of molecularly targeted therapies in AML. Once primarily associated with APL, DS...
Clinical Updates & Perspectices
Menin Inhibitors in AML: From Salvage Monotherapy to Frontline Combination Strategies
BTK Inhibitor Jaypirca is Now FDA-Approved & May Help Difficult-to-Treat Mantle Cell Lymphoma
PARADIGM Trial: Rethinking Induction Therapy in Fit Patients With AML
The Evolving Management of Anemia in Myelofibrosis
The Latest in Managing Anemia for Patients With Myelodysplastic Syndrome
Rytelo Gains FDA Approval for Lower-Risk Myelodysplastic Syndrome: Reducing Need For Blood Transfusions & Improving Quality of Life
The Latest: CML
Addressing Disparities
Treatment
Black Participation in Clinical Trials Is Imperative to Reduce Racial Disparities in Multiple Myeloma
By Kayle Waterhouse African Americans must be properly represented in clinical trials to ensure equal treatment for multiple myeloma and other cancers, top oncologists told SurvivorNet...